April 22, 2024

Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status

The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free and overall survival in patients with untreated, HER2-negative, locally advanced or metastatic gastric or ga...

The ASCO Post

May 09, 2024

Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer

Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric o...

The ASCO Post

May 03, 2023

First-Line Zolbetuximab Plus mFOLFOX6 in CLDN18.2-Positive, HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

As reported in The Lancet by Kohei Shitara, MD, and colleagues, the phase III SPOTLIGHT trial has shown significantly prolonged progression-free and overall survival with the addition of the anti–clau...

The ASCO Post

June 13, 2023

Study Illuminates Potential Marked Disparities in Federal Cancer Research Funding

Investigators have found that federal cancer research funding tends to be allocated more heavily toward cancers that occur more often in non-Hispanic White patients than those that occur more frequent...

The ASCO Post

May 13, 2024

Oral Rinse Could Provide Early Screening for Gastric Cancer

A simple oral rinse may lead to early detection of gastric cancer, according to new findings presented at Digestive Disease Week (DDW) 2024.

The ASCO Post

December 21, 2023

Expert Point of View: Elizabeth Smyth, MD

Dr. Elizabeth Smyth from Oxford University Hospitals NHS Foundation Trust provides insights on the promising results and challenges of CMG901, a targeted antibody-drug conjugate, for advanced gastric or gastroesophageal junction cancer treatment.

The ASCO Post

February 13, 2023

Expert Point of View: David Wang, MD, PhD

Dr. David Wang discusses the significant survival benefit shown by zolbetuximab in the SPOTLIGHT trial for advanced gastric cancer, shedding light on its potential as a predictive biomarker.

The ASCO Post

March 10, 2023

Expert Point of View: David Wang, MD, PhD

Dr. David Wang discusses the lasting clinical benefit demonstrated in CheckMate 649 and insights from the RATIONALE 305 study.

The ASCO Post

July 10, 2024

In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation

In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in t...

The ASCO Post